351 related articles for article (PubMed ID: 28669071)
1. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
John M; Cerdas S; Violante R; Deerochanawong C; Hassanein M; Slee A; Canovatchel W; Hamilton G
Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
6. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
Blonde L; Woo V; Mathieu C; Yee J; Vijapurkar U; Canovatchel W; Meininger G
Curr Med Res Opin; 2015 Nov; 31(11):1993-2000. PubMed ID: 26373629
[TBL] [Abstract][Full Text] [Related]
7. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
Sinclair AJ; Bode B; Harris S; Vijapurkar U; Shaw W; Desai M; Meininger G
J Am Geriatr Soc; 2016 Mar; 64(3):543-52. PubMed ID: 27000327
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
10. Effect of canagliflozin on liver function tests in patients with type 2 diabetes.
Leiter LA; Forst T; Polidori D; Balis DA; Xie J; Sha S
Diabetes Metab; 2016 Feb; 42(1):25-32. PubMed ID: 26575250
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Saroka RM; Kane MP; Busch RS; Watsky J; Hamilton RA
Endocr Pract; 2015 Dec; 21(12):1315-22. PubMed ID: 26307900
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
Gavin JR; Davies MJ; Davies M; Vijapurkar U; Alba M; Meininger G
Curr Med Res Opin; 2015; 31(9):1693-702. PubMed ID: 26121561
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.
Inagaki N; Kondo K; Yoshinari T; Maruyama N; Susuta Y; Kuki H
Diabetes Obes Metab; 2013 Dec; 15(12):1136-45. PubMed ID: 23782594
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
19. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
